BAY1817080
Aug 10, 2020
Merck; Bayer; Shionogi set to showcase their candidates indicated for Chronic RefractoryCough in the ATS Virtual Conference
Merck’s Gefapixant could become the first drug approved for Chronic Cough ATS 2020 Virtual is happening from August 5 to August 10, and it is exciting to watch major Respiratory /Pulmonary Pharmaceutical companies and their key presentations. Merck is worth mentioning here, as it is presenting key posters and...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
